超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

以色列Protalix Biotherapeutics
Protalix Biotherapeutics 公司是一家以色列的生物技術公司，以其獨有的植物細胞培養(yǎng)技術和生物反應器系統(tǒng)，來高效表達人類治療用蛋白。 公司準備通過這種技術平臺來大規(guī)模生產蛋白和抗體，為其它制藥和生物技術公司提供服務。其主要產品——治療高雪氏癥（ Gaucher's Disease ）的重組蛋白——即將進入臨床試驗。

We are a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on our proprietary ProCellEx? protein expression system. Using our ProCellEx? system we are developing a pipeline of proprietary recombinant therapeutic proteins based on our plant cell-based expression technology that target large, established pharmaceutical markets and that rely upon known biological mechanisms of action. Our initial commercial focus has been on complex therapeutic proteins, including proteins for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. We believe our ProCellEx? protein expression system will enable us to develop proprietary recombinant proteins that are therapeutically equivalent or superior to existing recombinant proteins currently marketed for the same indications.In addition, we believe our ProCellEx protein expression system will enable us to express and produce bio similar or "generic" versions of other recombinant proteins not protected through patents in a cost effective manner. Because we are targeting primarily biologically equivalent versions ("Biosimilar versions") of highly active, well-tolerated and commercially successful therapeutic proteins, we believe our development process is associated with relatively less risk compared to other biopharmaceutical development processes for novel therapeutic proteins.